drugset / Trial / NCT06021119

Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop System

NCT06021119

Phase 3 Completed 50 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelTreatment

Summary

Background: Ramadan Iftar meal typically causes glucose excursions. Dipeptidyl peptidase-4 inhibitors increase serum concentrations of glucagon-like peptide-1 and thus, decrease blood glucose levels with low risk of hypoglycemia. Aim: To investigate the efficacy and safety of vildagliptin as an add-on therapy among adolescents and young adults with type 1 diabetes mellitus (T1DM) on glucose excursions of Iftar Ramadan meals and glycemic metrics during advanced hybrid closed-loop (AHCL) treatment.

Timeline

Start
2023-03-23
Primary completion
2023-04-21
Completion
2023-04-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vildagliptin Other / unclassified 50 mg Oral

Indications

No indication recorded.